Barrier Therapeutics to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference

The i-Technology Media!	Register \| Log in

.NET · AJAX · CLOUD · ECLIPSE · FLEX · OPEN WEB · iPHONE · JAVA · LINUX · OPEN SOURCE · ORACLE · PBDJ · SEARCH · SILVERLIGHT · SOA · VIRTUALIZATION · WEB 2.0 · WIRELESS · XML

Comments

Improving the Efficiency of SOA-Based Applications

jhv1blz5 wrote: The article validated SOA as an IT architecture paradigm that can be leveraged in many ways. Taking data storage, scalability and application performance to a nifty level using SOA Application Grid infrastructure will no doubt enhance data and application performance on Oracle architecture platforms, it also has the promise of a cost effective and efficient IT delivery model. The very benefits of SOA.

Jul. 3, 2009 10:31 AM EDT

Cloud Computing | Virtualization
November 2 - 4
Register Today and SAVE !..

Did you read today's front page stories & breaking news?

Live Google News by SYS-CON!

Top Three Links You Must Click On

From the Wires

Barrier Therapeutics to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference

By: Marketwire .

Apr. 5, 2007 11:30 AM

PRINCETON, NJ -- (MARKET WIRE) -- 04/05/07 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that Dr. Geert Cauwenbergh, Chief Executive Officer, will participate in the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference.

The conference will be held at the Millennium Broadway Hotel in New York, NY on April 11 - April 12, 2007. Barrier Therapeutics is scheduled to present on Thursday, April 12, at 9:10 a.m. EDT (6:10 a.m. PDT).

The presentation will be available via a live webcast and can be accessed through the Investor Relations section of Barrier Therapeutics' corporate website at: www.barriertherapeutics.com. An archive of the presentation will be available for replay for 90 days.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact:
Barrier Therapeutics, Inc.
Anne M. VanLent
EVP & CFO
(609) 945-1202

Lazar Partners Ltd.
Gregory Gin, Investor Relations
(212) 867-1762

Published Apr. 5, 2007— Reads 242
Copyright © 2007 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.

About Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.